PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34632857-8 2021 At the gene level, IGF-1 inhibition of PBDE-209-induced cell cytotoxicity was through the activation of the PI3K/AKT and MEK/ERK signaling pathways in vitro because the effect of IGF-1 was blocked by the AKT inhibitor LY294002 and the ERK1/2 inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 252-259 insulin-like growth factor 1 Rattus norvegicus 19-24 34632857-8 2021 At the gene level, IGF-1 inhibition of PBDE-209-induced cell cytotoxicity was through the activation of the PI3K/AKT and MEK/ERK signaling pathways in vitro because the effect of IGF-1 was blocked by the AKT inhibitor LY294002 and the ERK1/2 inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 252-259 insulin-like growth factor 1 Rattus norvegicus 179-184 21092510-10 2010 The IGF-1-induced SCF expression was reduced significantly by a pretreatment of PD-98059 (23% in protein and 48% in mRNA, P<0.05). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 80-88 insulin-like growth factor 1 Rattus norvegicus 4-9 27511131-7 2016 Inhibition of Akt activation with LY294002 or by Rictor knockdown did not block the protective effect of IGF-1, while inhibition of MEK activity with PD98059 prevented Bim phosphorylation and blocked IGF-1 protection. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 150-157 insulin-like growth factor 1 Rattus norvegicus 200-205 23447091-7 2013 Additionally, IGF-I-stimulated CREB phosphorylation was blunted by the MAP kinase inhibitor, PD98059, but not by the PI3 kinase inhibitor, wortmannin. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 93-100 insulin-like growth factor 1 Rattus norvegicus 14-19 22537549-7 2012 PD98059 and LY294002 neutralize the preventive effects of IGF-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 insulin-like growth factor 1 Rattus norvegicus 58-63 25136768-9 2017 Either extracellular signal-regulated protein kinase (ERK1/2) inhibitor PD98059 or phosphatidylinositol 3-kinase (PI3 K) inhibitor LY294002 blocked the effect of IGF-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 72-79 insulin-like growth factor 1 Rattus norvegicus 162-167 24995704-7 2014 Immunoblotting and immunohistochemical analysis showed that the microinjection of LY294002 (0.6 pmol) or PD98059 (3.0 pmol) into the NTS attenuated the IGF-1-induced depressor effects and Akt or ERK phosphorylation in WKY rats. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 105-112 insulin-like growth factor 1 Rattus norvegicus 152-157 22490886-7 2012 The phosphorylation of Akt and PRAS40 induced by IGF-1 (100ng/ml) was inhibited by the phosphatidylinositide 3-kinase (PI3K) specific inhibitor LY294002 (50muM), while no inhibitory effect was observed for a MAPK kinase pathway specific inhibitor PD98059 nor a p38 MAPK inhibitor PD169316, suggesting that the phosphorylation of PRAS40 induced by IGF-1 is mediated by the PI3K pathway in PC12 cells and primary cultured neurons. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 247-254 insulin-like growth factor 1 Rattus norvegicus 49-54 20821260-6 2011 The presence of the phosphatidylinositol 3-kinase (PI3-K) inhibitor LY294002 and the mitogen-activated protein kinase kinases (MEK) inhibitor PD98059 blocked the effect of IGF-1 on BACE-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 142-149 insulin-like growth factor 1 Rattus norvegicus 172-177 18595745-17 2009 In contrast, the ERK/MAPK inhibitor PD98059 significantly inhibited the effect of IGF-1 on MMP-13 mRNA repression and enhanced IGF-1-induced Col2a1 mRNA expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 36-43 insulin-like growth factor 1 Rattus norvegicus 82-87 18595745-17 2009 In contrast, the ERK/MAPK inhibitor PD98059 significantly inhibited the effect of IGF-1 on MMP-13 mRNA repression and enhanced IGF-1-induced Col2a1 mRNA expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 36-43 insulin-like growth factor 1 Rattus norvegicus 127-132 16342423-6 2005 Here, it is shown that IGF1-dependent protein synthesis is completely blocked by PD98059, indicating that the Raf-Mek-Erk cascade is required for IGF1"s anabolic activity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 81-88 insulin-like growth factor 1 Rattus norvegicus 23-27 18278798-6 2008 Motor behavior tests and tyrosine hydroxylase immunoreactivity revealed that the inhibitor of the PI3K/Akt pathway (LY294002) blocked the survival effects of both estrogen and IGF-1, while an inhibitor of the MAPK/ERK signaling (PD98059) was ineffective. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 229-236 insulin-like growth factor 1 Rattus norvegicus 176-181 18453753-8 2008 In contrast, MAP kinase inhibitor PD98059 (10 micromol/l) significantly reduced the protective effect of IGF-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 34-41 insulin-like growth factor 1 Rattus norvegicus 105-110 15845624-5 2005 Coincubation of IGF-I with specific inhibitors of the p42/44 MAPK pathway (PD098059 or U0126) completely abolished the stimulatory effect of IGF-I on IGFBP-3 mRNA expression but did not affect increased IGFBP-5 mRNA levels. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 75-83 insulin-like growth factor 1 Rattus norvegicus 16-21 15845624-5 2005 Coincubation of IGF-I with specific inhibitors of the p42/44 MAPK pathway (PD098059 or U0126) completely abolished the stimulatory effect of IGF-I on IGFBP-3 mRNA expression but did not affect increased IGFBP-5 mRNA levels. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 75-83 insulin-like growth factor 1 Rattus norvegicus 141-146 18076874-9 2008 PD98059, an inhibitor for phosphorylation of extracellular signal-regulated kinase (ERK), but not wortmannin, that for protein kinase B phosphorylation, attenuated an increase in leucine incorporation into cardiomyocytes in the presence of either IGF-1 or endothelin-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 insulin-like growth factor 1 Rattus norvegicus 247-252 17335809-7 2007 IGF-1 activated the ERK1/2 signaling pathway in cultured hippocampal neurons, and the inhibitor PD98059 blocked the enhancement of sEPSCs induced by IGF-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 96-103 insulin-like growth factor 1 Rattus norvegicus 149-154 17365107-5 2007 Increased IGF-I secretion and inhibited IGFBP-1 secretion due to ethanol-induced p42/44 MAPK activity (at 30 min) was blocked by treatment with PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 144-151 insulin-like growth factor 1 Rattus norvegicus 10-15 16586540-8 2006 Furthermore, the changes in IGF-1 and IGFBP-1 secretion resulting from the increased betaine-induced p42/44 MAPK activity in primary cultured rat hepatocytes was blocked by treatment with the MAPK inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 207-214 insulin-like growth factor 1 Rattus norvegicus 28-33 16342423-6 2005 Here, it is shown that IGF1-dependent protein synthesis is completely blocked by PD98059, indicating that the Raf-Mek-Erk cascade is required for IGF1"s anabolic activity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 81-88 insulin-like growth factor 1 Rattus norvegicus 146-150 11027947-6 2000 In contrast, the inhibitor of MEK-1 activation, PD098059 (which reduced IGF-1-stimulated p42/p44 MAPK phosphorylation), had no effect on PDE3B activation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 48-56 insulin-like growth factor 1 Rattus norvegicus 72-77 15068962-7 2004 Concurrent treatment with the MAPK inhibitor PD98059 (10 microM) resulted in an inhibition of the IGF-I-mediated increase in IGFBP-5 and collagen alpha(1)(I) mRNAs, while concurrent treatment with the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin (100 nM) had no effect. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 45-52 insulin-like growth factor 1 Rattus norvegicus 98-103 12959952-5 2004 Our results show that 14 days of coinfusion of MAPK/ERK kinase inhibitor PD-098059 (PD) limited the phosphorylation of ERK and prevented IGF-I induced increases in protein (18%, P < 0.05 vs. 7%, not significant) or myofibrillar protein (23%, P < 0.01 vs. 5%, not significant). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 73-82 insulin-like growth factor 1 Rattus norvegicus 137-142 12959952-7 2004 The most notable impact on IGF-I signaling was a significant blunting of IGF-I induced increase in S6K1 phosphorylation by PD-98059 coinfusion ( approximately 5-fold, P < 0.001 vs. 3-fold, P < 0.01). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 123-131 insulin-like growth factor 1 Rattus norvegicus 27-32 12959952-7 2004 The most notable impact on IGF-I signaling was a significant blunting of IGF-I induced increase in S6K1 phosphorylation by PD-98059 coinfusion ( approximately 5-fold, P < 0.001 vs. 3-fold, P < 0.01). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 123-131 insulin-like growth factor 1 Rattus norvegicus 73-78 12239091-10 2002 IGF-I increased CREB phosphorylation at a concentration as low as 10 ng/ml, and this effect was inhibited by H89, a PKA inhibitor, and PD98059, a MAPK kinase inhibitor. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 135-142 insulin-like growth factor 1 Rattus norvegicus 0-5 11548882-4 2001 This hypertrophic effect of IGF-1 was blocked by genistein (tyrosine kinase inhibitor), PD98059 (MEK inhibitor). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 88-95 insulin-like growth factor 1 Rattus norvegicus 28-33 11256230-8 2000 A tyrosine kinase inhibitor (genistein), a MAPK inhibitor (PD-098059) and a P13 kinase inhibitor (wortmannin) could also suppress the antiapoptotic effects of IGF-I. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 59-68 insulin-like growth factor 1 Rattus norvegicus 159-164 15151916-5 2004 In contrast, inhibition of mitogen-activated protein (MAP) kinase with PD-98059 or U0126 abolished the stimulatory effect of IGF-I. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 71-79 insulin-like growth factor 1 Rattus norvegicus 125-130 14765977-18 2004 In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 162-169 insulin-like growth factor 1 Rattus norvegicus 68-73 14765977-18 2004 In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 162-169 insulin-like growth factor 1 Rattus norvegicus 191-196 14765977-18 2004 In addition, the analysis of the participation of a MAPK pathway in IGF-I regulation of Sertoli cell biological responses showed that the MAPK kinase inhibitors, PD98059 and U0126, decreased IGF-I-stimulated transferrin secretion while not modifying IGF-I-stimulated lactate levels. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 162-169 insulin-like growth factor 1 Rattus norvegicus 191-196 11683530-9 2001 The effect of zinc, IGF-I, or zinc plus IGF-I in increasing bone DNA synthesis activity was completely prevented by culture with PD98059 (10(-5) M), an inhibitor of mitogen-activated protein (MAP) kinase. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 129-136 insulin-like growth factor 1 Rattus norvegicus 20-25 11683530-9 2001 The effect of zinc, IGF-I, or zinc plus IGF-I in increasing bone DNA synthesis activity was completely prevented by culture with PD98059 (10(-5) M), an inhibitor of mitogen-activated protein (MAP) kinase. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 129-136 insulin-like growth factor 1 Rattus norvegicus 40-45 11228094-5 2001 The antiapoptotic effect of IGF-1 was blocked by LY294002 (an inhibitor of phosphatidylinositol 3-kinase) and by PD98059 (an inhibitor of extracellular signal-regulated kinase (ERK)). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 113-120 insulin-like growth factor 1 Rattus norvegicus 28-33 9927318-7 1999 The effect of IGF-I was blocked by PD98059, a specific inhibitor of the MAP kinase-activating kinase, but not by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 35-42 insulin-like growth factor 1 Rattus norvegicus 14-19 10788447-4 2000 The effect of IGF-1 was blocked by the phosphatidylinositide 3-kinase (PI3K) inhibitors LY294002 (50 micrometer) and wortmannin (0.5 micrometer), but not by the MEK inhibitor PD98059 (50 micrometer) or the p70 S6 kinase pathway inhibitor rapamycin (50 nm), suggesting that the stimulation of Akt by IGF-1 is mediated by the PI3K pathway. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 175-182 insulin-like growth factor 1 Rattus norvegicus 14-19 10579338-5 1999 Both LY 294002 and PD 98059 lowered the IGF-1-induced increase of HGF in the medium by about 40%, but LY 294002 was 10 times more potent than PD 98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 19-27 insulin-like growth factor 1 Rattus norvegicus 40-45 10579338-5 1999 Both LY 294002 and PD 98059 lowered the IGF-1-induced increase of HGF in the medium by about 40%, but LY 294002 was 10 times more potent than PD 98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 142-150 insulin-like growth factor 1 Rattus norvegicus 40-45 10873673-4 2000 These antiapoptotic effects of IGF-1 were blocked by PD-098059 (an MEK inhibitor) but not by bisindolylmaleimide I (BIM, a specific PKC inhibitor). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 53-62 insulin-like growth factor 1 Rattus norvegicus 31-36 10816436-7 2000 The presence of PD98059, an inhibitor of MEK (MAP-kinase/Erk kinase), during treatment with IGF-I partially inhibited the cAMP-dependent augmentation of DNA synthesis in response to IGF-I. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 16-23 insulin-like growth factor 1 Rattus norvegicus 92-97 10816436-7 2000 The presence of PD98059, an inhibitor of MEK (MAP-kinase/Erk kinase), during treatment with IGF-I partially inhibited the cAMP-dependent augmentation of DNA synthesis in response to IGF-I. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 16-23 insulin-like growth factor 1 Rattus norvegicus 182-187 9915817-8 1999 Inhibition of MAPK kinase with PD98059, PI 3-kinase with wortmannin, and p38 MAPK with SB203580 blocked IGF-I-mediated phosphorylation and transcriptional activation of CREB by 30-50% (p < 0.001). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 31-38 insulin-like growth factor 1 Rattus norvegicus 104-109 9490004-4 1998 IGF-1-stimulated protein synthesis was also significantly inhibited by PD-098059, staurosporine, and rapamycin, but not by wortmannin, in cardiac myocytes. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 71-80 insulin-like growth factor 1 Rattus norvegicus 0-5 8995241-8 1997 Blocking the mitogen-activated protein kinase pathway with the specific mitogen-activated protein kinase/extracellular-response kinase kinase inhibitor PD098059 (10(-5) M) inhibited the IGF-1 effect. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 152-160 insulin-like growth factor 1 Rattus norvegicus 186-191